Professor John Gribben
The research interest of my group focuses on immunological approaches to the treatment of haematological cancers. In particular, we are interested in understanding:
- The molecular mechanisms whereby cancer cells induce changes in the host immune system
- The use of allogeneic stem cell bone marrow transplant to induce a graft versus leukaemia effect
- Identification of the antigenic targets expressed by cancer cells
- Use of agents that will make tumour cells more susceptible to immune cell mediated killing, without impacting on the host immune system
I hold the Gordon Hamilton Fairley Chair of Medical Oncology at St. Bartholomew's Hospital, Barts Cancer Institute, Queen Mary, University of London. My doctoral studies were performed at University College London as the recipient of a Wellcome Trust Fellowship Award. I continued post-doctoral training with Professor Lee Nadler at the Dana-Farber Cancer Institute, Harvard Medical School.
In 1992, I was appointed to the Faculty at Harvard Medical School, where I remained as Associate Professor of Medicine and an Attending Physician at the Dana-Farber Cancer Institute and Brigham and Women's Hospital, until returning to London in 2005. I am a founding member of the CLL Research Consortium, Associate Editor of Blood and was elected a Fellow of the Academy of Medical Science.
My primary research interests include the immunotherapy of cancer (including stem cell transplantation), the identification of B-cell-tumour antigens; and the detection and treatment of minimal residual disease in leukaemia and lymphoma.
- CRUK Programme Grant – Applied Molecular Oncology
- NIH Programme Grant – CLL Research Consortium
- CLL Global Alliance – Immunological approaches to treat CLL
Gribben JG, O'Brien S. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol. 2011 Feb 10;29(5):544-50. PMID: 21220603
Woyach JA, Ruppert AS, Heerema NA, Peterson BL, Gribben JG, Morrison VA, Rai KR, Larson RA, Byrd JC. Chemoimmunotherapy With Fludarabine and Rituximab Produces Extended Overall Survival and Progression-Free Survival in Chronic Lymphocytic Leukemia: Long-Term Follow-Up of CALGB Study 9712. J Clin Oncol. 2011 Feb 14. [Epub ahead of print], PMID: 21321292
Greaves PJ, Gribben JG. Demonstration of Durable Graft Versus Lymphoma Effects in Hodgkin's Lymphoma. J Clin Oncol. 2011 Jan 31. [Epub ahead of print] PMID: 21282550
Gribben JG, Hosing C, Maloney DG. Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2011 Jan;17(1 Suppl):S63-70. PMID: 21195313
For additional publications, please click here.
Cancer Immunotherapy Group
- Professor John Gribben
- Professor Finbarr Cotter
- Dr Rebecca Auer
- Dr Jeff Davies
- Dr Li Jia
- Dr David Taussig
- Dr Alan Ramsay
Aims to develop immunotherapy approaches for the treatment of cancer, including stem cell transplantation; and to identify tumour antigens, the nature of the malignant stem cell and identification of targets for novel therapies.
- MRC Molecular and Cellular Medicine Board (MCMB), 2007-
- CRUK Clinical Trials Advisory Committee (CTAAC), 2008-
- British Society for Bone Marrow Transplantation Executive Board, 2009-
- CRUK Feasibility Study Committee (FSC) 2007-8
- Leukemia Lymphoma Research Fund Clinical Trials Advisory Panel (CTAP) 2007-
- International Workshop on non-Hodgkin's Lymphoma (iwNHL) Executive Board, 2002-
- International Workshop on Hodgkin Lymphoma – Programme Committee, 2007-
- NIH – NCI Initial Review Group Subcommittee D 2002-2005
- Cancer and Leukemia Group B, Correlative Science Committee 2002-2006
- American Society of Clinical Oncology, Patient communication subcommittee 2002-2004
Associate Editor, Blood, 2008-